KR20120049848A - 수족 피부반응 치료를 위한 알로푸리놀의 이용 - Google Patents

수족 피부반응 치료를 위한 알로푸리놀의 이용 Download PDF

Info

Publication number
KR20120049848A
KR20120049848A KR1020117028500A KR20117028500A KR20120049848A KR 20120049848 A KR20120049848 A KR 20120049848A KR 1020117028500 A KR1020117028500 A KR 1020117028500A KR 20117028500 A KR20117028500 A KR 20117028500A KR 20120049848 A KR20120049848 A KR 20120049848A
Authority
KR
South Korea
Prior art keywords
allopurinol
treatment
hfsr
medicament
induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020117028500A
Other languages
English (en)
Korean (ko)
Inventor
욜란다 로데머
Original Assignee
어드밴셀 어드밴스드 인 비트로 셀 테크놀로지스, 에스.에이
노베라 파르마, 에스. 엘.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어드밴셀 어드밴스드 인 비트로 셀 테크놀로지스, 에스.에이, 노베라 파르마, 에스. 엘. filed Critical 어드밴셀 어드밴스드 인 비트로 셀 테크놀로지스, 에스.에이
Publication of KR20120049848A publication Critical patent/KR20120049848A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117028500A 2009-04-29 2010-04-29 수족 피부반응 치료를 위한 알로푸리놀의 이용 Abandoned KR20120049848A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21489409P 2009-04-29 2009-04-29
EP09382058A EP2246057A1 (en) 2009-04-29 2009-04-29 Use of allopurinol for the treatment of hand foot skin reaction
US61/214,894 2009-04-29
EP09382058.7 2009-04-29

Publications (1)

Publication Number Publication Date
KR20120049848A true KR20120049848A (ko) 2012-05-17

Family

ID=40897536

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117028500A Abandoned KR20120049848A (ko) 2009-04-29 2010-04-29 수족 피부반응 치료를 위한 알로푸리놀의 이용

Country Status (22)

Country Link
US (2) US8623878B2 (https=)
EP (2) EP2246057A1 (https=)
JP (1) JP6007101B2 (https=)
KR (1) KR20120049848A (https=)
CN (1) CN102421436B (https=)
AR (1) AR076505A1 (https=)
AU (2) AU2010243594A1 (https=)
BR (1) BRPI1011971A2 (https=)
CA (1) CA2759085C (https=)
DK (1) DK2424538T3 (https=)
ES (1) ES2434366T3 (https=)
HR (1) HRP20131070T1 (https=)
IL (1) IL215831A (https=)
ME (1) ME01567B (https=)
MX (1) MX2011011529A (https=)
NZ (1) NZ595901A (https=)
PL (1) PL2424538T3 (https=)
PT (1) PT2424538E (https=)
RS (1) RS53005B (https=)
RU (1) RU2543325C2 (https=)
SI (1) SI2424538T1 (https=)
WO (1) WO2010125143A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025084793A1 (ko) * 2023-10-19 2025-04-24 (주) 수파드엘릭사 수족증후군 또는 수족피부반응의 예방 또는 치료용 약학 조성물

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013508295A (ja) 2009-10-16 2013-03-07 デューク・ユニヴァーシティ 薬物誘発性手足症候群を治療するための組成物および方法
CA2824933A1 (en) * 2011-01-18 2012-07-26 Vicus Therapeutics, Llc Pharmaceutical compositions and methods for making and using them
JP2021506958A (ja) 2017-12-13 2021-02-22 オンクォリティ ファーマシューティカルズ チャイナ エルティーディーＯｎｑｕａｌｉｔｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｈｉｎａ Ｌｔｄ． Ｅｇｆｒ阻害に関連する疾患を予防又は治療する方法
KR102831159B1 (ko) * 2018-04-16 2025-07-07 온퀄리티 파마슈티컬스 차이나 리미티드 암 치료의 부작용을 예방하거나 치료하기 위한 방법
US20200046703A1 (en) * 2018-08-09 2020-02-13 Asymmetric Therapeutics, Llc Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents
KR20240159565A (ko) 2022-01-05 2024-11-05 아시메트릭 테라퓨틱스, 엘엘씨 피부 증식성 장애 및 다른 피부 병태 치료를 위한 방법 및 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE66147T1 (de) * 1987-02-13 1991-08-15 Allergan Pharma Verwendung von pteridinen und/oder purinen oder eines xanthinoxidase-hemmers zur herstellung eines arzneimittels zur behandlung von genetisch bedingten degenerativen netzhauterkrankungen.
WO1994005293A1 (en) 1992-09-04 1994-03-17 Aws Shakir Mustafa Salim Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol
GB9218711D0 (en) 1992-09-04 1992-10-21 Salim Aws S M Skin cancer treatment
JP3106817B2 (ja) 1993-11-02 2000-11-06 富士電機株式会社 漏電遮断器
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6060083A (en) * 1999-04-01 2000-05-09 Topical Technologies, Inc. Topical DMSO treatment for palmar-plantar erythrodysethesia
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
EP1609468A3 (en) * 2000-11-22 2006-01-25 Rxkinetix, Inc. A composition on the basis of a sulfur-containing antioxidant and its use for the manufacture of a medicament for treating mucositis
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
SE0100873D0 (sv) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
EP1455888B1 (en) 2001-08-29 2009-04-29 PharmaKodex Limited Topical administration device
EP1461033B1 (en) * 2001-11-29 2013-02-27 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
DE10200578A1 (de) 2002-01-09 2003-07-10 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
US6979688B2 (en) * 2002-02-12 2005-12-27 Ford John P Treatment method against side-effects of chemotherapy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CA2528378A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
CA2528359A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
US20050148910A1 (en) * 2003-12-24 2005-07-07 Gregory Skover Apparatus having a skin-contactable element containing an agent
JP4405326B2 (ja) 2004-06-28 2010-01-27 株式会社東芝 ランドリー機器
EP1791535B1 (en) 2004-09-17 2008-07-30 BioMAS Ltd. Novel tellurium compounds and their use as immunomodulators
WO2007138103A1 (en) 2006-06-01 2007-12-06 Nobera Pharma, S.L. Use of allopurinol for the treatment of palmar plantar erythrodysesthesia

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025084793A1 (ko) * 2023-10-19 2025-04-24 (주) 수파드엘릭사 수족증후군 또는 수족피부반응의 예방 또는 치료용 약학 조성물

Also Published As

Publication number Publication date
EP2424538A1 (en) 2012-03-07
HK1168042A1 (en) 2012-12-21
JP6007101B2 (ja) 2016-10-12
CA2759085C (en) 2016-08-16
ME01567B (me) 2014-04-20
ES2434366T3 (es) 2013-12-16
IL215831A0 (en) 2012-01-31
EP2424538B1 (en) 2013-08-14
RS53005B (sr) 2014-04-30
RU2011148355A (ru) 2013-06-10
CA2759085A1 (en) 2010-11-04
RU2543325C2 (ru) 2015-02-27
US20140080845A1 (en) 2014-03-20
CN102421436A (zh) 2012-04-18
NZ595901A (en) 2013-11-29
US20100280051A1 (en) 2010-11-04
BRPI1011971A2 (pt) 2016-04-26
AR076505A1 (es) 2011-06-15
WO2010125143A1 (en) 2010-11-04
IL215831A (en) 2016-02-29
DK2424538T3 (da) 2013-11-04
AU2010243594A1 (en) 2011-11-10
JP2012525358A (ja) 2012-10-22
US8623878B2 (en) 2014-01-07
SI2424538T1 (sl) 2013-12-31
HRP20131070T1 (hr) 2013-12-20
PL2424538T3 (pl) 2014-05-30
CN102421436B (zh) 2014-05-07
AU2016228193A1 (en) 2016-11-03
PT2424538E (pt) 2013-11-07
EP2246057A1 (en) 2010-11-03
MX2011011529A (es) 2012-02-08

Similar Documents

Publication Publication Date Title
JP5389980B2 (ja) 手足症候群の治療のためのアロプリノールの使用
AU2016228193A1 (en) Use of allopurinol for the treatment of hand foot skin reaction
CN101460172B (zh) 别嘌醇在制备治疗手足综合征的药物中的用途
HK1168042B (en) Use of allopurinol for the treatment of hand foot skin reaction

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20111129

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150428

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160520

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20170320

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee